Navigation Links
Bioniche Reports the Passing of its Board Chair
Date:4/18/2008

- Hy Isenbaum served as Chair of the Bioniche Board of Directors since 1999

-

BELLEVILLE, ON, April 18 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its long-time Board Chair, Mr. Hy Isenbaum, has passed away.

"This is very sad news for Bioniche Life Sciences," said Graeme McRae, the Company's President & CEO. "As Board Chair, Mr. Isenbaum contributed financial expertise and vigilance regarding the Company's financial statements. Additionally, he has provided a high level, conservative, ethical tone that permeates the whole Company in terms of regulatory affairs, product development, and overall conduct of the business. He will be greatly missed by all who knew and worked with him. He was a mentor and a friend."

Mr. Isenbaum was Chair of the Board since 1999, when Bioniche Life Sciences Inc. was formed through an amalgamation of Bioniche Inc., Renaissance Life Sciences Inc., and Vetrepharm Animal Health Inc.

Mr. Isenbaum was a Fellow Chartered Accountant and the Founder of the firm Soberman, Isenbaum and Colomby. As the Managing Partner, a position he held until 1993, he built his firm to be the 15th largest accounting practice in Canada. He was a Chairman of the Board and Chairman Emeritus of the Mount Sinai Hospital in Toronto. He was appointed by the Ontario Ministry of Health as Ombudsman to the Medical Review Committee of the College of Physicians and Surgeons. He served on the Board of Directors of the Samuel Lumenfeld Research Institute in Toronto and was instrumental in the establishment of the Institute. Mr. Isenbaum was also a Governor of the Weizman Institute of Science in Israel and sat on the boards of a number of private and public companies.

In honour of Mr. Isenbaum's extensive contributions to Bioniche, the "Hy Isenbaum Award" has been created. This will be presented annually to the Bioniche employee who best epitomizes the Bioniche spirit - whether at work or in the community.

A new Chair will be appointed at the Board's next quarterly meeting in early May.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of Canada's Top Ten Life Sciences Companies for 2008. For more information, please visit http://www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Converts a Portion of its Debt to Equity
2. Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
3. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution
4. Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
5. Bioniche Reports Fiscal 2008 Second Quarter
6. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
7. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
8. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
9. Bioniche Reports Fiscal 2008 First Quarter
10. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
11. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that due ... Texas, they are expanding their presence in Dallas. One of the most exciting parts ... new jobs to the Dallas and Forth Worth market. STAT takes pride in treating ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... after surgery as possible. With this in mind, SIGVARIS has created a new ... blood clot) during bed rest and provide the benefits of graduated compression when ...
(Date:12/8/2016)... Francisco, California (PRWEB) , ... December 08, 2016 , ... ... coaches, has raised an $18M Series B led by Canvas Ventures . Other ... the capital to scale its mobile platform to serve more consumers who are managing ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne ... offices headquartered in Hamilton County, is embarking on a charity drive with the ... finding new homes for orphaned or neglected senior dogs in the Cincinnati region, ...
(Date:12/8/2016)... AZ (PRWEB) , ... December 08, 2016 , ... ... firm with offices that serve communities in and around the greater Phoenix metropolitan ... the Homeless Youth Connection. , The mission of the Homeless Youth Connection is ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 KEY FINDINGS The ... in 2017-2023. Various reasons for growth of the medical ... incidences of chronic diseases, high recovery cost of injuries ... Medical lifting sling refers to an assistive device ... These slings connect to the lift and hold the ...
(Date:12/8/2016)... Dec. 8, 2016 Allergy Diagnostics Market: ... and tests that are used to determine the ... milk, or drugs etc. in the samples by ... immune system. The report on global allergy diagnostics ... the market. The report consists of an executive ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has ... and Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Electrodes Market is poised to grow at a CAGR of around ... the market is witnessing include advancements in extracellular microelectrode arrays and ...
Breaking Medicine Technology: